RGS16 promotes glioma progression and serves as a prognostic factor
Open Access
- 22 April 2020
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (8), 791-803
- https://doi.org/10.1111/cns.13382
Abstract
Background RGS protein family members have recently became new potentially promising therapeutic targets in many cancers. However, as a key member of RGS family, RGS16 has seldom been studied in glioma. The present study was designed to investigate the prognostic value and biological function of RGS16 based on large‐scale databases and functional assays in vitro. Methods Here, we performed comprehensive analysis for the expression characteristic of RGS16 in Chinese Glioma Genome Atlas (CGGA) microarray database with 301 patients and validated in The Cancer Genome Atlas (TCGA) microarray and RNA sequencing database. Student's t‐test, one‐way ANOVA test and long‐rank test were used to assess differences between groups. Kaplan‐Meier survival, univariate and multivariate Cox analysis and ROC curve were used to estimate the survival distributions. Biological implication of abnormal expression of RGS16 in glioma was also explored. Functional analysis of RGS16 was performed in several glioblastoma (GBM) cell lines. R language and SPSS were used for statistical analysis and graphical work. Results We found that the expression of RGS16 was positively related to the grade of glioma. High level of RGS16 commonly gathered in glioma of mesenchymal subtype and wild‐type IDH1. Moreover, higher expression level of RGS16 was found to be significantly correlated with poor prognosis. The univariate and multivariate Cox regression analysis and ROC curve showed that RGS16 was an independent prognostic factor for glioma patients. Gene ontology analysis, gene set enrichment analysis, and gene set variation analysis suggested that the overexpression of RGS16 tightly related to cell proliferation, migration, epithelial‐mesenchymal transition (EMT), immune and inflammatory response of glioma. Knockdown of RGS16 in glioma cell lines also showed that RGS16 promoted the malignant progress of glioma cell lines. Conclusions RGS16 plays an important role in glioma progression and serves as an independent prognostic factor, especially in GBM patients.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7192057)
- National Natural Science Foundation of China (81702460, 81802994, 81972816)
This publication has 35 references indexed in Scilit:
- RGS16 promotes glioma progression and serves as a prognostic factorCNS Neuroscience & Therapeutics, 2020
- The regulator of G-protein signaling RGS16 promotes insulin secretion and β-cell proliferation in rodent and human isletsMolecular Metabolism, 2016
- CGCG clinical practice guidelines for the management of adult diffuse gliomasCancer Letters, 2016
- The potential role of regulator of G‐protein signaling 16 in cell motility mediated by δEF1 family proteinsFEBS Letters, 2015
- Timing Is Everything: GTPase Regulation in PhototransductionInvestigative Ophthalmology & Visual Science, 2013
- Primary brain tumours in adultsThe Lancet, 2012
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastomaCancer, 2009
- Modulation of G Protein Signaling Normalizes Tumor VesselsCancer Research, 2009
- Follicular Dendritic Cell Regulation of CXCR4-Mediated Germinal Center CD4 T Cell MigrationThe Journal of Immunology, 2004
- Cellular Regulation of RGS Proteins: Modulators and Integrators of G Protein SignalingPharmacological Reviews, 2002